European Parliament Lead on Clinical Trials Regulation gets tough on transparency
This article was originally published in Scrip
Executive Summary
The lead legislator on the proposed Clinical Trials Regulation at the European Parliament has called for major transparency-related changes to be made to the draft legislation. Glenis Willmott has suggested, among other things, that the proposed text of the CTR be amended to clarify that "clinical trial data should not be considered commercially confidential once a marketing authorization has been obtained [by a drug company]".